Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age1-24
SponsorIndiana University

About this trial

The goal of this pragmatic clinical trial is to learn if the drug surfactant given by a less invasive technique works to treat respiratory distress in preterm infants in low- and middle-income African countries where invasive ventilators are unavailable. It will also learn about the safety of the less invasive surfactant administration (LISA) technique. The main questions it aims to answer are:

Does surfactant given by a less invasive surfactant administration technique improve survival in preterm infants in low- and middle-income countries? What medical problems do participants have when receiving surfactant given by the less invasive surfactant administration technique?

Researchers will implement the less invasive surfactant administration technique and see if it works to treat respiratory distress in preterm infants compared to preterm who did not receive surfactant.

Participants with respiratory distress who are being treated with continuous positive airway pressure and caffeine citrate will:

Receive surfactant replacement therapy by the less invasive surfactant administration technique.

Be monitored for complications Be followed throughout their hospitalization to determine their survival rate.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Birth weight between 750 and 2000 grams or gestational age between 24- and 35 weeks.

Silverman Anderson Score ≥5 before or after CPAP treatment.

Admitted to a study site within 24 hours of life.

Disqualifiers

Major congenital or genetic anomalies.

Active pulmonary hemorrhage.

Major craniofacial anomalies that preclude the successful use of CPAP

Trial design

Design model

Crossover

Treatments tested in this trial

  • Surfactant

    Drug

    Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)

Treatment groups

1,512 Participants
are divided into 2 treatment groups
Group A: Non-LISA GroupNo intervention 0 interventions
Group B: LISA GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Hospital Survival

Survival to hospital discharge

Time frame
Through hospitalization, an average of 6 months

Secondary outcomes

1

Incidence of major preterm neonatal morbidity

Intraventricular hemorrhage, Retinopathy of Prematurity, Bronchopulmonary Dysplasia, Surgical Necrotizing Enterocolitis and Culture Positive Sepsis

Time frame
Through hospitalization, an average of 6 months
2

The incidence of pneumothorax

Air leaks into the space between your lung and chest wall

Time frame
Through hospitalization, an average of 6 months
3

Hospital survival at seven day

Survival rates assessed at day seven of life

Time frame
7 days following birth

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Indiana University

Lead sponsor

Coefficient Giving (Formerly Open Philanthropy)

Collaborator